Spots Global Cancer Trial Database for cemiplimab
Every month we try and update this database with for cemiplimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Cemiplimab in Adults With Cervical Cancer | NCT03257267 | Squamous Cell C... Recurrent or Me... | Cemiplimab Investigator Ch... | 18 Years - | Regeneron Pharmaceuticals | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | NCT04465487 | Squamous Cell C... | REGN6569 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | NCT03889912 | Cutaneous Squam... Basal Cell Carc... | Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | NCT04590326 | Ovarian Cancer Fallopian Tube ... Primary Periton... Endometrial Can... | REGN5668 Cemiplimab REGN4018 Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT02760498 | Advanced Cutane... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab/Peg-Interferon-α in Advanced CSCC | NCT05729139 | Cutaneous Squam... Squamous Cell C... Advanced Squamo... | Cemiplimab-Rwlc PEG-IFN alfa-2a | 18 Years - | Baptist Health South Florida | |
| Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT05376553 | Locally Advance... | Cemiplimab Cisplatin Docetaxel | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | NCT05259709 | Advanced Solid ... Metastatic Soli... | 89Zr˗DFO˗REGN50... cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| THIO Sequenced With Cemiplimab in Advanced NSCLC | NCT05208944 | Carcinoma, Non-... | 6-Thio-2'-Deoxy... Cemiplimab | 18 Years - | Maia Biotechnology | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | NCT06121180 | Metastatic Uvea... | ZIV-Aflibercept Cemiplimab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| CemiplimAb Survivorship Epidemiology | NCT03836105 | Cutaneous Squam... Basal Cell Carc... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | NCT06384820 | Cutaneous Squam... | cemiplimab fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | NCT05662397 | Solid Tumor, Ad... Relapsed Cancer Refractory Canc... | HST-1011 Cemiplimab | 18 Years - | HotSpot Therapeutics, Inc | |
| Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery | NCT03565783 | Recurrent Cutan... Resectable Cuta... Stage II Cutane... Stage III Cutan... Stage IV Cutane... | Cemiplimab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03580694 | Carcinoma, Non-... | REGN4659 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | NCT04626635 | Advanced Solid ... | REGN7075 cemiplimab Platinum-based ... | 18 Years - | Regeneron Pharmaceuticals | |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | NCT04050436 | Cutaneous Squam... Advanced Cutane... Metastatic Cuta... | Cemiplimab RP1 | 18 Years - | Replimune Inc. | |
| ASP8374 + Cemiplimab in Recurrent Glioma | NCT04826393 | Glioblastoma Recurrent Gliob... | ASP8374 cemiplimab | 18 Years - | Dana-Farber Cancer Institute | |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | NCT04543071 | Pancreatic Canc... Adenocarcinoma ... Adenocarcinoma | Motixafortide Cemiplimab Gemcitabine Nab paclitaxel | 18 Years - | Columbia University | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | NCT05064085 | Hormone Recepto... | Cemiplimab Capecitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL | NCT04729725 | Advanced Malign... Metastatic Mali... Unresectable Ma... | Anti-TGF-beta M... Cemiplimab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | NCT03005782 | Malignancies | REGN3767 cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Trial of INI-4001 in Patients With Advanced Solid Tumours | NCT06302426 | Advanced Solid ... | INI-4001 Nivolumab Pembrolizumab Cemiplimab Avelumab Atezolizumab Durvalumab | 18 Years - | Inimmune Corporation | |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT05864144 | Solid Tumor, Ad... Advanced Solid ... Head and Neck C... Breast Cancer Colon Cancer Pancreatic Canc... Gastric Cancer Esophageal Canc... Prostate Cancer Uterine Cancer Cervix Cancer Ovarian Cancer Kidney Cancer Bladder Cancer Thyroid Cancer Melanoma Sarcoma Advanced Cancer Metastatic Canc... Refractory Canc... Non Small Cell ... | SNS-101 (anti-V... Cemiplimab | 18 Years - | Sensei Biotherapeutics, Inc. | |
| Study of Cemiplimab in Adults With Cervical Cancer | NCT03257267 | Squamous Cell C... Recurrent or Me... | Cemiplimab Investigator Ch... | 18 Years - | Regeneron Pharmaceuticals | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | NCT04913220 | Malignant Melan... Squamous Cell C... | THOR-707 Cemiplimab | 18 Years - | Sanofi | |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | NCT04291105 | Melanoma Head and Neck S... Colo-rectal Can... | VV1 Cemiplimab | 18 Years - | Vyriad, Inc. | |
| PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | NCT03132636 | Carcinoma, Basa... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab for Secondary Angiosarcomas | NCT04873375 | Secondary Angio... Locally Advance... Metastasis | Cemiplimab | 18 Years - | Radboud University Medical Center | |
| TOP 2301: Neoadjuvant Chemo for NSCLC | NCT06385262 | Non Small Cell ... | Alirocumab Cemiplimab Chemotherapy | 18 Years - | Duke University | |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | NCT05840770 | Metastatic Lung... Metastatic Mali... Stage IV Lung C... | Biospecimen Col... Cemiplimab Computed Tomogr... Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | NCT06205836 | Colorectal Canc... | Cemiplimab Fianlimab | 70 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | NCT03669718 | Squamous Cell C... HPV16 Positive | ISA101b Cemiplimab Placebo | 18 Years - | ISA Pharmaceuticals | |
| A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | NCT03972657 | Metastatic Cast... Clear Cell Rena... | REGN5678 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab for Secondary Angiosarcomas | NCT04873375 | Secondary Angio... Locally Advance... Metastasis | Cemiplimab | 18 Years - | Radboud University Medical Center | |
| PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | NCT03132636 | Carcinoma, Basa... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | NCT06205836 | Colorectal Canc... | Cemiplimab Fianlimab | 70 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca | NCT04988074 | HPV-Related Squ... | Cemiplimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL | NCT04729725 | Advanced Malign... Metastatic Mali... Unresectable Ma... | Anti-TGF-beta M... Cemiplimab | 18 Years - | M.D. Anderson Cancer Center | |
| Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | NCT03492489 | Cutaneous Squam... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Study of Cemiplimab in Adults With Cervical Cancer | NCT03257267 | Squamous Cell C... Recurrent or Me... | Cemiplimab Investigator Ch... | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | NCT05840770 | Metastatic Lung... Metastatic Mali... Stage IV Lung C... | Biospecimen Col... Cemiplimab Computed Tomogr... Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery. | NCT06161441 | Resectable Non-... | Fianlimab Cemiplimab Pemetrexed Paclitaxel Carboplatin Cisplatin Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | NCT05142189 | Non-Small Cell ... | BNT116 Cemiplimab Docetaxel Carboplatin Paclitaxel | 18 Years - | BioNTech SE | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | NCT05352672 | Melanoma | Fianlimab Cemiplimab Pembrolizumab Placebo | 12 Years - | Regeneron Pharmaceuticals | |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | NCT04460456 | HER2 Positive S... | SBT6050 pembrolizumab Cemiplimab | 18 Years - | Silverback Therapeutics | |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT05785767 | Advanced Non-Sm... | fianlimab cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT04862650 | Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a... | Carboplatin Cemiplimab Paclitaxel | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | NCT04315701 | Recurrent Skin ... Resectable Skin... Stage I Skin Ca... Stage II Skin C... Stage III Skin ... | Cemiplimab Resection | 18 Years - | University of Southern California | |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | NCT03491683 | Glioblastoma | INO-5401 INO-9012 Cemiplimab Radiation Thera... Temozolomide | 18 Years - | Inovio Pharmaceuticals | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | NCT06121180 | Metastatic Uvea... | ZIV-Aflibercept Cemiplimab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma | NCT05538988 | Mycosis Fungoid... | Cemiplimab | 18 Years - | AHS Cancer Control Alberta | |
| A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | NCT05574101 | Cutaneous Squam... Skin Cancer Squamous Cell C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... | Cemiplimab Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | NCT05535023 | Squamous Cell C... Oropharynx Canc... Head and Neck C... | SAR444245 Cemiplimab | 18 Years - | M.D. Anderson Cancer Center | |
| Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | NCT04373083 | Hodgkin Lymphom... | Cemiplimab Involved-site r... | 18 Years - 75 Years | Regeneron Pharmaceuticals | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | NCT04291105 | Melanoma Head and Neck S... Colo-rectal Can... | VV1 Cemiplimab | 18 Years - | Vyriad, Inc. | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | NCT05557591 | Advanced Non-Sm... | BNT116 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Deep sequencIng in Cutaneous Squamous CEll caRciNomas | NCT05878288 | Cutaneous Squam... Cutaneous Squam... Neoplasms Non-melanoma Sk... | Cemiplimab | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT05785767 | Advanced Non-Sm... | fianlimab cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer | NCT04428671 | Metastatic Skin... Recurrent Skin ... | Cemiplimab Radiation Thera... Therapeutic Con... | 18 Years - | Emory University | |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | NCT06412198 | Metastatic Colo... KRAS G12C Mutat... | Cetuximab Cemiplimab Adagrasib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC | NCT06219317 | NSCLC Stage IV | Cemiplimab Placebo | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | NCT05142189 | Non-Small Cell ... | BNT116 Cemiplimab Docetaxel Carboplatin Paclitaxel | 18 Years - | BioNTech SE | |
| LAG3 PET Imaging in Advanced Solid Tumors | NCT04706715 | Metastatic Soli... | 89Zr-DFO-REGN37... Cemiplimab | 18 Years - | University Medical Center Groningen | |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT04862650 | Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a... | Carboplatin Cemiplimab Paclitaxel | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
